Checked
Zymeworks Inc.
Nasdaq: ZYME · Pharmaceutical Preparations · Middletown, DE
- Revenue
- $106M
- +38.9% vs. prior year
- Net income
- -$81.13M
- -76.6% net margin
- Total assets
- $346.5M
- Diluted EPS
- -$1.08
Company details
As reported to the SEC
- SEC CIK
- 1937653
- Stock
- Nasdaq: ZYME
- Legal Entity Identifier (LEI)
- 894500AHOYAGYLYZJL67
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- Headquarters
- 108 Patriot Drive, Suite A, Middletown, DE 19709
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- December 31
- Filer status
- Non-accelerated filer, Smaller reporting company
- Phone
- (302) 274-8744
- Employer ID (EIN)
- 88-3099146
- Last annual report
- 03/02/2026
- Last quarterly report
- 08/06/2026
Formerly: Zymeworks Delaware Inc. (until 10/13/2022)
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|---|
| Revenue | $106M | $76.3M | $76.01M | $412.5M | $26.68M |
| Operating income | -$92.55M | -$137.1M | -$138.1M | $130.5M | -$215.6M |
| Net income | -$81.13M | -$122.7M | -$118.7M | $124.3M | -$211.8M |
| Diluted earnings per share | -$1.08 | -$1.62 | -$1.72 | $1.90 | -$4.61 |
| Research and development | $137M | $134.6M | $143.6M | $208.6M | $199.8M |
| Total assets | $346.5M | $463.1M | $580.9M | $648.7M | $389.1M |
| Total liabilities | $78.03M | $124.3M | $116.1M | $155.8M | $140M |
| Shareholders' equity | $268.5M | $338.8M | $464.8M | $493M | $249.1M |
| Cash and cash equivalents | $41.16M | $66.1M | $157.6M | $400.9M | $201.9M |
| Cash from operations | -$33.01M | -$110.1M | -$118.3M | $144.1M | -$192.5M |
| Capital expenditures | $1.52M | $1.99M | $2.47M | $8.15M | $12.4M |
Federal and state records filed under the name Zymeworks Inc.
Matched by the company name and by the subsidiary names it lists in SEC filings and other public records, after removing endings like Inc., Corp. and Holdings. Records marked Subsidiary were filed under a subsidiary name. A subsidiary that is not listed in those records is not included, and an unrelated business with the same name can appear.
Work visa sponsorship
Certified H-1B and PERM green card filings with the Department of Labor
| Employer on filing | H-1B | PERM |
|---|---|---|
| Zymeworks Biopharmaceuticals Inc.Subsidiary · Seattle, WA | 1 | 0 |
Subsidiaries
9 companies that Zymeworks Inc. owns or controls, as listed in its SEC annual report (Exhibit 21), GLEIF ownership records or USAspending
| Subsidiary | Listed in |
|---|---|
| Zymeworks BC Inc. | SEC 10-K |
| Zymeworks Biopharmaceuticals Inc. | SEC 10-K |
| Zymeworks CallCo ULC | SEC 10-K |
| Zymeworks ExchangeCo Ltd. | SEC 10-K |
| Zymeworks General Partner ULC | SEC 10-K |
| Zymeworks Lifesciences Pte. Ltd. | SEC 10-K |
| Zymeworks Management Inc. | SEC 10-K |
| Zymeworks Pharmaceuticals Limited | SEC 10-K |
| Zymeworks Royalty Partnership Limited | SEC 10-K |
Recent filings
60 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
44 insider ownership reports (Forms 3, 4, 5 and 144) were filed about Zymeworks Inc. in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other pharmaceutical preparations
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Johnson & JohnsonJNJ | New Brunswick, NJ | $94.19B | $26.8B |
| Eli Lilly & CoLLY | Indianapolis, IN | $65.18B | $20.64B |
| Merck & Co., Inc.MRK | Rahway, NJ | $65.01B | $18.25B |
| Pfizer IncPFE | New York, NY | $62.58B | $7.77B |
| AbbVie Inc.ABBV | North Chicago, IL | $61.16B | $4.23B |
| Astrazeneca PLCAZN | Cambridge, United Kingdom | $58.74B | $10.22B |
| Bristol Myers Squibb CoBMY | Princeton, NJ | $48.19B | $7.05B |
| Abbott LaboratoriesABT | Abbott Park, IL | $44.33B | $6.52B |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is Zymeworks Inc.'s CIK number?
- Zymeworks Inc.'s SEC Central Index Key (CIK) is 1937653.
- What is Zymeworks Inc.'s stock ticker?
- Zymeworks Inc. trades as Nasdaq: ZYME.
- What was Zymeworks Inc.'s revenue?
- Zymeworks Inc. reported revenue of $106M for the fiscal year ended Dec 31, 2025, +38.9% from the year before.
- When does Zymeworks Inc.'s fiscal year end?
- Zymeworks Inc.'s fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is Zymeworks Inc. headquartered?
- Zymeworks Inc.'s principal executive office on file with the SEC is in Middletown, DE.
- What companies does Zymeworks Inc. own?
- Zymeworks Inc. lists 9 subsidiaries in its SEC filings and other public records, including Zymeworks BC Inc., Zymeworks Biopharmaceuticals Inc., Zymeworks CallCo ULC.
- Does Zymeworks Inc. sponsor H-1B visas?
- Department of Labor records show 1 certified H-1B filings and 0 certified PERM filings under the name Zymeworks Inc.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026